Background: Monoclonal antibodies constitute a relatively new class of therapeutic agent
designed to interact with specific target antigens. Monoclonal antibodies can be created to
deplete cell lineages or antagonize receptors for which small molecule drugs are not
available. Because of their accessibility, proteins expressed on the surface of immune
system cell lineages are appealing targets for monoclonal antibody therapies. Review
Summary: To review monoclonal antibodies currently under investigation for treatment of …